Assembly Biosciences (ASMB) Total Current Liabilities (2010 - 2026)

Assembly Biosciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $35.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 24.95% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $35.0 million (down 24.95% YoY), while the FY2025 annual figure was $48.8 million, up 2.04% from the prior year.
• Total Current Liabilities was $35.0 million for Q1 2026 at Assembly Biosciences, down from $48.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $53.4 million in Q3 2025 to a low of $7.1 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $30.8 million across 5 years, with a median of $38.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities sank 53.87% in 2023, then surged 483.78% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $16.3 million in 2022, then jumped by 140.7% to $39.2 million in 2023, then grew by 21.87% to $47.8 million in 2024, then gained by 2.04% to $48.8 million in 2025, then retreated by 28.26% to $35.0 million in 2026.
• The last three Total Current Liabilities figures came in at $35.0 million (Q1 2026), $48.8 million (Q4 2025), and $53.4 million (Q3 2025), per Business Quant data.